chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vomiting, diarrhea, body aches, intense abdominal pain, and intense lower right back pain for 12 days. Primary care provided an X-Ray, referred immediately to ER because I was unable to urinate other than a few drops, was dehydrated, and needed fluids. I was given a shot of Zofran and a prescription of zofran tablets as well. Bloodwork was abnormal in multiple areas. I also had difficulty taking a deep breaths several occasions but with slow deep breathing I was able to do so. At ER I was given fluids, water, and received an ultrasound and CT scan with contrast to determine if there were any potential gallbladder, appendix, or kidney stone issues. All scans were normal and I was sent home to increase fluid intake, take zofran as directed, and seek assistance if I worsened. In total I was having active vomiting and diarrhea for 12 days, it persisted for several days after the ER visit, until 9-4-21.  The dr visit and ER visit were on 8-31-2021. I continued to have intermittent diarrhea through 9-15-21 as well as one more vomiting experience for overnight hours between  2:00 am-8:00 am on 9-15-21.  At present I have no symptoms  besides an occasional need to work to take a deep breath.
On 02/20/2002 the pt received JEV and typhoid as part of her out-processing to overseas. She remained in the clinic for the required 30 mins after the vaccination and experienced only soreness at the injectionsite. Few hours later she began shaking and crying, experiencing chills, feeling disoriented and fainted. She then was taken to ER for observation. She had a previous adverse event to vaccines in June 1994. She received OPV, MGC, typhoid, cholera, and plague vaccines at the same time. She believes that her symptoms were likely due to receiving so many vaccines at once. following this event she was able to tolerate all other required vaccinations without incident until 02/20/2002.
This spontaneous report was received from a hospital employee concerning a male patient of an unknown age. The patient's concurrent conditions, medical history, historical drugs and concomitant therapies were not reported. On 30-MAR-2017, the patient was received the first of VARIVAX lot number M033213 (dose, route and expiration date were not reported) for prophylaxis, with a sterile diluent (dose, lot number and expiration date were not reported). Then, on 14-APR-2017, the patient was inadvertently administered his second dose of VARIVAX lot number M018436 (dose, route and expiration date were not reported) for prophylaxis, with a sterile diluent (dose, lot number and expiration date were not reported). No adverse effects were reported. Additional information has been requested.
Pfizer x2 vaccinated patient admitted through ED due to hypoxia.  Patient died during admission for COVID/hypoxia.  Provider discharge note below:  "75 YO year old male with past medical history of arthritis, myasthenia gravis. He is presenting to  Hospital per direction of PCP due to low oxygen saturation.    Per discussion with patient and wife, his symptoms started on 11/28/21 with URI symptoms. His cough progressed with some mucopurulent sputum. He worked, as a vet, up until 12/9/21, when his shortness of breath made it too difficult to continue working. He came to the emergency department on 12/10 and was noted to be hypoxic at that time. He received dexamethasone and supplemental O2, which improved his dyspnea temporarily. His symptoms again worsened and he called his PCP just prior to arrival. Per PCP note, patient was saturating between 73% and 83%. He was advised to come to the emergency department.    On initial vitals significant for hypoxia of 72% on 3.0 lpm. His SpO2 was improved to 98% on 15 lpm NRB. Other vitals were unremarkable. CBC demonstrated normocytic anemia at baseline and left shift. Chemistries demonstrated mild hyperglycemia of 132 and isolated elevation of AST. BNP was elevated at 1544. pCT was mildly elevated at 0.14. Troponin delta was negative. D-dimer was elevated at 2200.    1. Acute hypoxic respiratory failure: due to COVID-19. Pt remains on HFNC 40L @ 100% FiO2. S/p 6 day course of ceftriaxone and doxycycline. 1/2 initial  blood cultures positive for staph epi. This is likely a contaminant but was covered with antibiotics and repeat cultures were negative. Leukocytosis down trended, repeat CXR was stable appearing. In the early morning of 12/31, patient was found to have pulled his mask off and unresponsive. STAT ABG revealed pH 6.97, lactate of 14.3. telemetry w/ v-tach. Patient was placed back on mask and given 2 amps of bicarb with improvement in oxygenation and cardiac rhythm. Subsequent rapid response was called about 2 hours later where patient was exhibiting agonal breathing, then expired shortly after. "
Inappropriate schedule of drug administration; no adverse effect Information has been received from a physician concerning two 4 month old patients who were vaccinated PO with a dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human-bovine). It was unknown if medical attention was sought and no adverse experiences were reported. Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available. Additional information has been requested.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 63-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 12Sep2023 as dose 1, single (Lot number: HH7595) at the age of 62 years, in left arm for COVID-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "Known allergies: Dust" (unspecified if ongoing); "Known allergies: Bananas" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: COVID-19 vaccine (dose 1, single; manufacturer unknown), for COVID-19 immunisation; COVID-19 vaccine (dose 2 single; manufacturer unknown), for COVID-19 immunisation; COVID-19 vaccine (dose 3 (booster), single; manufacturer unknown), for COVID-19 immunisation; COVID-19 vaccine (dose 4 (booster), single; manufacturer unknown), for COVID-19 immunisation; COVID-19 vaccine (dose 5 (booster), single; manufacturer unknown), for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (Oct2023) Negative; (Oct2023) Negative; (Oct2023) Positive. Therapeutic measures were taken as a result of vaccination failure, COVID-19. Additional information: The patient was treated with Paxlovid from 15Oct2023 to 20Oct2023. After 2 negative tests, runny nose returned and a positive test.  No follow-up attempts are possible. No further information is expected.
Hurt a little bit when I got the shot, and my arm was sore later on that day; Hurt a little bit when I got the shot and my arm was sore later on that day; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a 75-year-old patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis.   On an unknown date, the patient received RSV vaccine. On an unknown date, less than a day after receiving RSV vaccine, the patient experienced pain (Verbatim: Hurt a little bit when I got the shot, and my arm was sore later on that day) and pain in arm (Verbatim: Hurt a little bit when I got the shot and my arm was sore later on that day).The outcome of the pain and pain in arm were not reported.   It was unknown if the reporter considered the pain and pain in arm to be related to RSV vaccine.   It was unknown if the company considered the pain and pain in arm to be related to RSV vaccine.   Additional Information: GSK Receipt Date: 26-SEP-2023 This case was reported by a patient via interactive digital media. The reporter stated that his/her doctor recommended it because he/she was 75 years old.  The patient got the RSV shot and insurance paid for it.  It hurt a little bit when he/she was got the shot and his/her arm was sore later on that day but other than that he/she had no reaction. The follow up would not possible as no contact details were available.
pimples in face and neck; inflamed eyelid; overall body aches for 10 days; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 26Mar2021 16:00 (Batch/Lot number: unknown) at the age of 56 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Allergy" (unspecified if ongoing), notes: Known allergy: sulfites; "Sulfonamide allergy" (unspecified if ongoing), notes: Known allergy: Sulfa drugs; "Penicillin allergy" (unspecified if ongoing), notes: Known allergy: Penicillin; "Factor V Leiden heterozygote" (unspecified if ongoing), notes: Factor V Leiden heterozygous. Concomitant medication(s) included: VITAMIN D NOS; ZINC; MAGNESIUM; VITAMIN B 12 [VITAMIN B12 NOS]. Past drug history included: Erythromycin, reaction(s): "drug allergy", notes: Known allergy: erythromycin. The following information was reported: ACNE (non-serious) with onset 26Mar2021 19:00, outcome "recovering", described as "pimples in face and neck"; BLEPHARITIS (non-serious) with onset 26Mar2021 19:00, outcome "recovering", described as "inflamed eyelid"; PAIN (non-serious) with onset 26Mar2021 19:00, outcome "recovering", described as "overall body aches for 10 days". Therapeutic measures were not taken as a result of acne, blepharitis, pain.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
dizzy; weak; funny taste at the back of her mouth; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy), ASTHENIA (weak) and TASTE DISORDER (funny taste at the back of her mouth) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, the patient experienced DIZZINESS (dizzy), ASTHENIA (weak) and TASTE DISORDER (funny taste at the back of her mouth). The patient was treated with IBUPROFEN on 02-Mar-2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, DIZZINESS (dizzy), ASTHENIA (weak) and TASTE DISORDER (funny taste at the back of her mouth) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product information was not provided by the reporter.
Day of shot: Muscle tightness after injection which has never subsided since then Following week: tingling and muscle spasms in left arm and left side of back which have never subsided since then  Following month and thereafter: Difficulty walking, spasms from the knee to the ankle, must use walker to get out of bed and go to bathroom, yeast infections, urinary tract infections, and dizziness/lightheadedness all of which symptoms were not present prior to the shot
At 2:00 am on the morning of March 6, 2021 I woke up with terrible chills, upset stomach and a very rapid heartbeat that continued until 5:30 am.   The remainder of the day I had a horrible headache.
MILD PETECHIAE; DRUG EXPOSURE DURING BREASTFEEDING; This spontaneous report received from a consumer concerned a 6 week old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, transmammary, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the subject experienced mild petechiae, and drug exposure during breastfeeding. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from mild petechiae, and drug exposure during breastfeeding. This report was non-serious.
Faint rash upper left arm approx 2" from sight of injection - No other complaints or concerns
Reticular rash across lower lumbar area, several flaccid bullae along the patient's back, left side of abdomen, and left arm.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 80-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 05Feb2021 as dose 1, single (Lot number: EL9262), in left arm, on 27Feb2021 as dose 2, single (Lot number: EN6205), in left arm and on 07Oct2021 as dose 3 (booster), single (Lot number: WAG09477) at the age of 79 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 25Apr2022 at 10:00 as dose 4 (booster), single (Lot number: 059M21A), in right arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Past drug history included: Cipro, reaction(s): "known allergies: Cipro", notes: Known allergies: Cipro Keflex; Keflex, reaction(s): "known allergies: Keflex", notes: Known allergies: Cipro Keflex. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: Three days after testing negative; negative, notes: Three days after testing negative; positive, notes: I tested positive for Covid again. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: If vaccine received reported as Yes. Other medication in 2weeks reported as No. Anti-viral details: Product: Covid 19 Treatment, brand: Paxlovid, treatment start date: 03Jun2022, treatment stop date: 07Jun2022, Adverse event reported as Three days after testing negative I started to have symptoms. Two days later I tested positive for Covid again.
Patient fainted after immunizations were given. Patient was nervous and worked up prior to receiving vaccine. Mother stood in front of patient in chair and patient rested head on mother. RN rubbed back and fanned patient. Patient monitored for 15 minutes. No injury and incident resolved. Child has fear of needles.
Patient ordered a Janssen vaccine.  Patient was actually administered a Pfizer vaccine.  No symptoms or adverse events occured.
19JUN97 asleep till 11AM awakened by mom t104, vomiting x2;MD office pertussis/viral?/UTI ? 20JUN97 fever no v/v;
This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 79-year-old female patient who received SHINGRIX (batch number L9CS4, expiry date 22nd February 2021) for prophylaxis. Co-suspect products included Flu Vaccine (Name Unknown) for prophylaxis. On 6th September 2018, the patient received SHINGRIX. On an unknown date, the patient received Flu Vaccine (Name Unknown). On 6th September 2018, less than a day after receiving SHINGRIX, the patient experienced rash. On an unknown date, the outcome of the rash was recovered/resolved. It was unknown if the reporter considered the rash to be related to SHINGRIX. Additional case details were reported as follows: The patient also received high flu vaccine manufactured by Sanofi at time of SHINGRIX administration. The patient broke out in a rash across torso after receiving SHINGRIX vaccine. It was unknown if the reporter considered the rash to be related to Flu Vaccine (Name Unknown).
Lightheadness from Day1-present (Day 7). I feel dizzy and lightheaded all the time. Mild headache occurred from Day 1-4.
mom states about 9PM 8FEB93 noticed blister on rt leg when recvd vax; took to ER @ MD told to keep clean; poss allergic to shot;
Pt vax w/ hepta B; devel redness, itching + swelling at inject site for 20 minutes.  MD felt that reaction not related to vax.
?Pfizer-BioNTech COVID-19 Vaccine EUA?  gout had been quiescent but flared severely beginning about 9 days after second injection, requird Naproxen, and lasted over a week.
pt recv vax 22OCT97 & 25OCT97 was seen in office w/erythematous urticarial rash all over the body head to toe;pt recv celestone 1/2 IM rash cleared;
lower back pain; nerve burning sensation; dizziness; high fever; intense headache; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 31Aug2021 10:00 (Lot number: FC 3180) at the age of 53 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Lyme disease" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (Product: COVID 19, Brand: Pfizer, Lot number: FC3180, Lot unknown: False, Administration date: 10Aug2021, Vaccine location: Left arm, Dose number:1), administration date: 10Aug2021, when the patient was 53 years old, for COVID-19 Immunisation, reaction(s): "High fever", "Chills", "Aches".  The following information was reported: BACK PAIN (non-serious) with onset 31Aug2021 11:30, outcome "recovering", described as "lower back pain"; BURNING SENSATION (non-serious) with onset 31Aug2021 11:30, outcome "recovering", described as "nerve burning sensation"; DIZZINESS (non-serious) with onset 31Aug2021 11:30, outcome "recovering", described as "dizziness"; PYREXIA (non-serious) with onset 31Aug2021 11:30, outcome "recovering", described as "high fever"; HEADACHE (non-serious) with onset 31Aug2021 11:30, outcome "recovering", described as "intense headache". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of back pain, burning sensation, dizziness, pyrexia, headache.  Additional information: Patient did not receive any other vaccine in four weeks. Patient did not receive any other medications in two weeks. Patient tested COVID post vaccination. Patient had no known allergies.  No follow-up attempts are possible. No further information is expected.
Arm became swollen; Arm was little sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Arm was little sore) and VACCINATION SITE SWELLING (Arm became swollen) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 101A21A) for COVID-19 vaccination.     No medical history is provided and concomitant are produced.  Concomitant products included OLODATEROL HYDROCHLORIDE, TIOTROPIUM BROMIDE MONOHYDRATE (STIOLTO RESPIMAT) for an unknown indication.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced VACCINATION SITE PAIN (Arm was little sore). On 10-Mar-2021, the patient experienced VACCINATION SITE SWELLING (Arm became swollen). On 04-Mar-2021, VACCINATION SITE PAIN (Arm was little sore) had resolved. At the time of the report, VACCINATION SITE SWELLING (Arm became swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Within 20 hours of shot, developed severe rash/hives over both arms, legs and ankles. I went to urgent care 24 hours later, received an injection of Medrol 125mg and prescriptions for Medrol Pak, Benadryl and Pepcid.
sharp pain started shooting up leg, to my knee; slight headache; sharp pain started shooting up leg, to my knee; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 23-Apr-2021 and was forwarded to Moderna on 23-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sharp pain started shooting up leg, to my knee), HEADACHE (slight headache) and ARTHRALGIA (sharp pain started shooting up leg, to my knee) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001C21A and 019B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Apr-2021, the patient experienced PAIN IN EXTREMITY (sharp pain started shooting up leg, to my knee), HEADACHE (slight headache) and ARTHRALGIA (sharp pain started shooting up leg, to my knee). The patient was treated with IBUPROFEN for Adverse event, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (sharp pain started shooting up leg, to my knee), HEADACHE (slight headache) and ARTHRALGIA (sharp pain started shooting up leg, to my knee) outcome was unknown.            Concomitant medication was not provided.   This case was linked to MOD-2021-089394 (Patient Link).
17 year old female received .25ml Moderna Booster shot. Patient was not over 18 when vaccine was administered.
Punctured vial left at room temperature (approximately 75 degrees) for 24 hours. Patient received one dose.
can't lift his arm; feeling a lot of numbness; This is a spontaneous report from a contactable consumer (patient). A 59-year-old male patient received second dose BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration in arm right on 07Jul2021 (Lot Number: FA6780) as a single dose at the age of 59-year-old for covid-19 immunisation.  Medical history included hypertension (diagnosed a million years ago). The patient previously received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route on 03Jun2021 (Lot Number: EV0179 or EVI079) as a single dose at the age of 59-year-old for covid-19 immunisation. The patient's concomitant medications were not reported.  The patient feeling a numbness started a few hours after the shot and unable to lift his arm started on 07Jul2021 night. The outcome of the events was not recovered.  No follow-up attempts are possible; No further information is expected.